In mantle cell lymphoma, whether 18 F-FDG PET/CT or flow cytometry provide superior diagnostic performance compared to biopsy in the determination of bone marrow involvement and enhance prognostic predictive value
Retrospective analysis compares diagnostic performance of PET/CT and flow cytometry with biopsy in mantle cell lymphoma, suggesting enhanced prognostic value.
Key Points
The study aims to assess the diagnostic performance of 18F-FDG PET/CT and flow cytometry as alternatives to bone marrow biopsy for detecting bone marrow involvement and predicting prognosis in mantle cell lymphoma.
Retrospective analysis of 122 patients diagnosed with mantle cell lymphoma who underwent PET/CT and bone marrow examinations.
Assessment of sensitivity, specificity, positive predictive value, and negative predictive value for PET/CT and flow cytometry compared to biopsy results.
Survival analysis included 97 patients with complete data to evaluate prognostic factors for progression-free and overall survival.
Sensitivity of PET/CT was 57.4% with specificity of 55.9%.
Flow cytometry sensitivity was 90.7% with specificity of 77.9%, indicating stronger performance than PET/CT.
Multivariate analysis identified several independent prognostic factors impacting progression-free survival and overall survival, with a ratio of lymphoma cells ≥ 30% being pivotal.